Biogen Earnings Reports

Biogen reported Q4 2024 revenue of $2.46 billion, a 3% increase year-over-year. GAAP diluted EPS was $1.83, up 7% YoY, while Non-GAAP diluted EPS reached $3.44, up 17% YoY. Growth was primarily driven by rare disease revenue and biosimilars, which offset declines in multiple sclerosis products.

Biogen reported Q3 2024 revenue of $2.5 billion, with a GAAP diluted EPS of $2.66 and a Non-GAAP diluted EPS of $4.08. The company is increasing its full year 2024 Non-GAAP diluted EPS guidance to between $16.10 and $16.60.

Biogen reported second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28. The company is raising its full year 2024 financial guidance.

Biogen reported a decrease in total revenue by 7% year-over-year, but an increase in both GAAP and Non-GAAP EPS. The company is reaffirming its full-year financial guidance with Non-GAAP EPS expected to grow by approximately 5%. LEQEMBI launch uptake accelerated and SKYCLARYS launch is progressing well.

Biogen reported Q4 2023 revenue of $2.4 billion, with GAAP diluted EPS of $1.71 and Non-GAAP diluted EPS of $2.95. The company is focusing on operational execution and building upon the progress of recent new product launches to drive sustainable growth. Full year 2024 financial guidance includes Non-GAAP EPS of $15.00 to $16.00, representing approximately 5% growth versus 2023 at the mid-point.

Biogen reported a slight increase in revenue for Q3 2023, alongside a GAAP diluted EPS loss. However, the company highlighted advancements in its Alzheimer's disease program with LEQEMBI and the acquisition of Reata Pharmaceuticals. The implementation of the "Fit for Growth" program is expected to drive bottom-line growth.

Biogen reported Q2 2023 results with a revenue of $2,456 million and GAAP diluted EPS of $4.07. The company is focused on shifting resources to high-value creation areas, including investments in prioritized pipeline and new product launches, alongside cost-saving initiatives.

Biogen's first quarter 2023 revenue reached $2,463 million, with a GAAP diluted EPS of $2.67 and a Non-GAAP diluted EPS of $3.40. The company is focused on potential launches in Alzheimer’s disease and ALS, while also prioritizing R&D and optimizing its operating model.

Biogen reported Q4 2022 revenue of $2,544 million, with a GAAP diluted EPS of $3.79 and a Non-GAAP diluted EPS of $4.05. The company is strategically focused on growth drivers such as LEQEMBI in Alzheimer’s disease and zuranolone in depression, while also working to diversify its product portfolio and improve R&D productivity.

Biogen reported a revenue of $2,508 million for Q3 2022, a 10% decrease compared to the prior year. GAAP diluted EPS was $7.84, while Non-GAAP diluted EPS was $4.77. The company made significant progress with the Phase 3 study of lecanemab for early Alzheimer's disease and raised its full-year 2022 financial guidance.

Biogen reported a decrease in second-quarter revenue compared to the previous year, but raised its full-year financial guidance due to better-than-expected topline performance and continued cost management. The company continued to face revenue declines due to generic and biosimilar competition for TECFIDERA and RITUXAN. However, it made progress in bringing new potential treatments to patients suffering from Alzheimer’s disease and depression.

Biogen's first quarter 2022 results showed a decrease in revenue by 6% compared to the prior year, with GAAP diluted EPS at $2.06 and Non-GAAP diluted EPS at $3.62. The company is focusing on near-term operational priorities to drive renewed growth and value creation.

Biogen reported a Q4 2021 revenue of $2,734 million, a 4% decrease compared to the prior year. GAAP diluted EPS was $2.50, while Non-GAAP diluted EPS reached $3.39. The company is actively engaging with the Centers for Medicare and Medicaid Services on ADUHELM reimbursement and progressing its pipeline with key data readouts and regulatory filings expected in 2022.

Biogen reported third quarter 2021 financial results, with total revenue of $2,779 million and GAAP diluted EPS of $2.22. The potential uptake of ADUHELM in the U.S. is delayed, but the company continues to believe in its long-term potential. Biogen has continued to execute well across its leading MS, SMA and biosimilars businesses.

Biogen reported a 25% decrease in total revenue compared to the prior year, with $2,775 million. GAAP diluted EPS was $2.99, and Non-GAAP diluted EPS was $5.68. The company received accelerated approval for ADUHELM and FDA Breakthrough Therapy designation for lecanemab.

Biogen reported a decrease in first-quarter revenue compared to the previous year, but saw consistent performance across its multiple sclerosis, spinal muscular atrophy, and biosimilars portfolios. The company raised its full-year earnings guidance, anticipating a transformative year with potential regulatory decisions and pivotal readouts.

Biogen reported Q4 2020 revenue of $2,853 million and GAAP EPS of $2.32. The company is awaiting regulatory decision on aducanumab for Alzheimer's disease and anticipates a financial reset in 2021 due to TECFIDERA generics.

Biogen reported Q3 2020 results with a revenue of $3,376 million, a GAAP diluted EPS of $4.46, and a Non-GAAP diluted EPS of $8.84. The company is progressing with aducanumab and has a new share repurchase authorization of $5.0 billion.

Biogen reported Q2 2020 revenues of $3.7 billion, a 2% increase compared to Q2 2019. GAAP diluted EPS increased 22% to $9.59, while Non-GAAP diluted EPS increased 12% to $10.26. The company completed the submission of the BLA for aducanumab in Alzheimer's disease in the U.S.

Biogen reported Q1 2020 revenues of $3.5 billion, a 1% increase compared to Q1 2019. GAAP diluted EPS increased by 13%, while Non-GAAP diluted EPS increased by 31%. The company is progressing with the U.S. regulatory filing for aducanumab and has entered a collaboration with Sangamo Therapeutics for gene regulation therapies.

Biogen reported Q4 2019 revenues of $3.671 billion, a 4% increase compared to Q4 2018. GAAP diluted EPS was $8.08, a 71% increase, while Non-GAAP diluted EPS was $8.34, a 19% increase. Full year 2019 revenues were $14.378 billion, a 7% increase year-over-year.